Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Osteoporos Int. 2009 May 13;21(1):167–177. doi: 10.1007/s00198-009-0953-7

Table 3.

Mean +/− SD baseline biomarkers by case-control status and by randomized group: hip fracture cases vs. controls.

Cases Controls
E+P, E PBOa E+P, E PBOa
N Mean (SD) N Mean (SD) P-valueb N Mean (SD) N Mean (SD) P-valueb P-valuec
Total Estradiol (pg/ml) 88 11.69 (8.47) 131 10.19 (8.12) 0.19 127 12.32 (8.49) 90 13.24 (25.21) 0.70 0.15
Free Estradiol (pg/ml) 88 0.29 (0.21) 131 0.25 (0.22) 0.17 127 0.32 (0.25) 90 0.32 (0.52) 0.94 0.05
Bioavailable E2 (pg/ml) 88 7.23 (5.32) 131 6.25 (5.61) 0.20 127 8.23 (6.40) 90 8.41 (13.79) 0.90 0.03
SHBG (µg/dl) 95 1.56 (0.72) 136 1.73 (0.81) 0.09 134 1.37 (0.68) 97 1.36 (0.61) 0.84 <.0001
*a

Placebo.

*b

p-value from a linear model modeling the biomarker of interest as a function of HT status.

*c

p-value from a linear model modeling the biomarker of interest as a function of cases-control status.